Publications
95
Citations
918
Est. group size
~27
Recurring co-author estimate
Active years
29
Publishing since 1998
Tamio Okimoto's research centers on lung cancer, particularly EGFR-mutated non-small cell lung cancer (NSCLC), and its treatment with targeted therapies like osimertinib and afatinib, along with drug resistance mechanisms. The work also spans respiratory diseases more broadly, including COPD, asthma, idiopathic pulmonary fibrosis, and pleural mesothelioma, often combining clinical case reports with imaging and biomarker studies. This research would suit students interested in clinical pulmonology, oncology drug response, and translational studies connecting molecular findings to patient care.
Publication output has fluctuated over the past decade, with a dip around 2020 and 2024, but shows a strong resurgence in 2025-2026, suggesting renewed or increased research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of <i>De Novo</i> Mutations During <i>In Vitro</i> Exposure
Anticancer Research · 2026
- Pleural mesothelioma with net-like structures
Internal Medicine · 2026
- A Predicted FEV1/FVC Model Based on a Simple Respiratory Questionnaire for Early Diagnosis of COPD in Shimane Cohort, Japan
International Journal of COPD · 2026
- Unsupervised comprehensive CT imaging clusters reveal distinct morphological phenotypes in asthma: insights from two prospective cohorts
Respiratory Research · 2026
- Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation
Respirology · 2026
- Time course of postmortem procedures in a palliative care unit
Frontiers in Health Services · 2026
- The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)
European Journal of Cancer · 2025
- Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through <scp>CaMKII</scp> Activation in <scp>EGFR</scp> ‐Mutated <scp>NSCLC</scp>
Cancer Science · 2025
- Pure Red Cell Aplasia That Developed 13 Years After Thymoma Treatment: A Case Report and Literature Review
Thoracic Cancer · 2025
- Inhibition of Small-cell Lung Cancer Angiogenesis by Irinotecan Metronomic Chemotherapy and Irinotecan Plus Everolimus
Anticancer Research · 2025
- The Afatinib Response to EGFR E709G-mutated Lung Cancer
Internal Medicine · 2025
- Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety
Anticancer Research · 2025
- A case of lung adenocarcinoma with EGFR exon 19 deletion/insertion mutation (T751_I759delinsS) showing response to Osimertinib
Respiratory Medicine Case Reports · 2025
- Do Not Eat Before a Positron Emission Tomography-Computed Tomography (PET/CT) Scan: A Case Report
Cureus · 2025
- Response to Letter to the Editor on "The Afatinib Response to EGFR E709G-mutated Lung Cancer"
Internal Medicine · 2025
- Internal Medicine×10
- Anticancer Research×4
- Cancer Science×3
- Respirology Case Reports×3
- Journal of Clinical Oncology×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile